Treatment-emergent mutations in myelodysplastic syndrome with del(5q) – lenalidomide related or disease-intrinsic clonal evolution?
Sign Up to like & getrecommendations! Published in 2024 at "Blood Cancer Journal"
DOI: 10.1038/s41408-024-01027-5
Abstract: TO THE EDITOR: Myelodysplastic syndrome (MDS) with del(5q) is a subcategory of MDS without excess blasts ( 22% has been shown to portend inferior overall and leukemia-free survival [2] and, along with therapy-related disease, was… read more here.
Keywords: del lenalidomide; mds del; disease; treatment ... See more keywords